SCNI — Scinai Immunotherapeutics Share News
0.000.00%
Last trade - 00:00- $0.02m
- $3.28m
- $1.31m
NASDAQ RESUMED AT 09:00 AM
NASDAQ RESUMED AT 08:20 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 08:20 AM
NASDAQ RESUMED AT 07:55 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:55 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Israel's Scinai Q1 net income turns positive on acquisition gain
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:37 AM
Brief: Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Brief: Scinai Reports Full-Year 2025 Results, With Cdmo Revenues Doubling And Strategic Expansion Through Recipharm Collaboration
Brief: Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Brief: Scinai Signs Second Amendment To Pincell Option Agreement And Submits Revised €12 Million Non-Dilutive Feng Application To Advance Pc111 Through Human Proof Of Concept
Brief: Scinai Reports Nine-Month 2025 Results As CDMO Growth Continues And Nanoabs Pipeline Advances
Brief: Scinai Immunotherapeutics Awarded Israel Innovation Authority Grant To Expand Fill-And-Finish CDMO Capabilities
Brief: Scinai Immunotherapeutics Files Prospectus For Offer & Sale Of Up To 4.8 Mln ADS By YA II PN
SEC Filing
U.S. STOCKS ON THE MOVE-Owens & Minor ,Scinai , Vermilion Energy
Scinai more than doubles after Italian approval for biotech acquisition